Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma

BACKGROUND: Cancer patients with POLE or POLD1 mutations may be excellent candidates for immune checkpoint inhibitors (ICIs) therapy and have favorable prognosis, but their potential in stomach adenocarcinoma (STAD) remains unknown. Therefore, the clinical significance of POLE and POLD1 mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Mingyu, Cui, Haiyan, Zhang, Lu, Zhao, Kuo, Jia, Xiaochen, Jin, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841685/
https://www.ncbi.nlm.nih.gov/pubmed/35261896
http://dx.doi.org/10.21037/tcr-21-1601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841685/
https://www.ncbi.nlm.nih.gov/pubmed/35261896
http://dx.doi.org/10.21037/tcr-21-1601

Ejemplares similares